Acadia Healthcare’s Review Following Strong Q4 Results
<p>Analysts at RBC Capital provided their views on <a href='https://financialmodelingprep.com/financial-summary/ACHC'>Acadia Healthcare Company, Inc. (NASDAQ:ACHC)</a> following the company’s recently posted Q4 results, with EPS of $0.81 coming in better than the consensus estimate of $0.68. </p>
<p>According to the analysts, the company’s strong results reflected strong demand and labor cost management despite a tough environment, while initial 2022 guidance exceeded expectations thanks in part to strong 2021 M&A execution. </p>
<p>According to the brokerage, the company remains well-positioned to capitalize on increased demand for addiction and mental health treatment through the pandemic. Management’s balanced organic and inorganic growth strategy should continue to provide incremental upside in an attractive industry with secular tailwinds. </p>
<p>The company expects full 2022-year EPS in the range of $2.85-$3.15, compared to the consensus of $2.91, and revenue in the range of $2.55-2.6 billion, compared to the consensus of $2.48 billion.</p>

NASDAQ:ACHC